Your browser doesn't support javascript.
loading
De novo design of protein minibinder agonists of TLR3.
Adams, Chloe S; Kim, Hyojin; Burtner, Abigail E; Lee, Dong Sun; Dobbins, Craig; Criswell, Cameron; Coventry, Brian; Kim, Ho Min; King, Neil P.
Afiliación
  • Adams CS; Institute for Protein Design, University of Washington, Seattle, WA, 98195 USA.
  • Kim H; Department of Biochemistry, University of Washington, Seattle, WA, 98195 USA.
  • Burtner AE; Center for Biomolecular & Cellular Structure, Institute for Basic Science (IBS), Daejeon 34126, South Korea.
  • Lee DS; Institute for Protein Design, University of Washington, Seattle, WA, 98195 USA.
  • Dobbins C; Department of Biochemistry, University of Washington, Seattle, WA, 98195 USA.
  • Criswell C; Center for Biomolecular & Cellular Structure, Institute for Basic Science (IBS), Daejeon 34126, South Korea.
  • Coventry B; Institute for Protein Design, University of Washington, Seattle, WA, 98195 USA.
  • Kim HM; Department of Biochemistry, University of Washington, Seattle, WA, 98195 USA.
  • King NP; Institute for Protein Design, University of Washington, Seattle, WA, 98195 USA.
bioRxiv ; 2024 Apr 18.
Article en En | MEDLINE | ID: mdl-38659926
ABSTRACT
Toll-like Receptor 3 (TLR3) is a pattern recognition receptor that initiates antiviral immune responses upon binding double-stranded RNA (dsRNA). Several nucleic acid-based TLR3 agonists have been explored clinically as vaccine adjuvants in cancer and infectious disease, but present substantial manufacturing and formulation challenges. Here, we use computational protein design to create novel miniproteins that bind to human TLR3 with nanomolar affinities. Cryo-EM structures of two minibinders in complex with TLR3 reveal that they bind the target as designed, although one partially unfolds due to steric competition with a nearby N-linked glycan. Multimeric forms of both minibinders induce NF-κB signaling in TLR3-expressing cell lines, demonstrating that they may have therapeutically relevant biological activity. Our work provides a foundation for the development of specific, stable, and easy-to-formulate protein-based agonists of TLRs and other pattern recognition receptors.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: BioRxiv Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: BioRxiv Año: 2024 Tipo del documento: Article